Literature DB >> 2991163

Mitoxantrone: propensity for free radical formation and lipid peroxidation--implications for cardiotoxicity.

R F Novak, E D Kharasch.   

Abstract

Results of comparative studies on stimulation of the rates of cofactor consumption, superoxide generation and hydrogen peroxide production by mitoxantrone (Novantrone; dihydroxyanthracenedione; MXN), ametantrone (AM), doxorubicin (DOX) and daunorubicin (DNR) in the presence of NADPH-cytochrome P-450 reductase, NADH dehydrogenase, or rabbit hepatic microsomes have been reported. MXN and AM were substantially less effective in stimulating the rate of cofactor oxidation, superoxide formation or hydrogen peroxide production relative to the anthracyclines. In the presence of P-450 reductase, the rate of NADPH oxidation or superoxide generation produced by 100 microM MXN or AM was only 15% and 2% respectively of that produced by 100 microM anthracycline. The effects of MXN and AM on lipid peroxidation in hepatic microsomes, cardiac sarcosomes and cardiac mitochondria were determined and compared with those produced by ADM. MXN and AM at 50 microM inhibited the basal rate of NADPH-dependent rabbit liver microsomal lipid peroxidation by 50%; in contrast, DOX enhanced the rate of hepatic microsomal lipid peroxidation by 2- and 2.5-fold at 100 and 200 microM, respectively. Rabbit cardiac sarcosomal NADPH-dependent lipid peroxidation was inhibited completely at 100 microM anthracenedione. NADH-dependent lipid peroxidation in cardiac mitochondria was diminished by 50 microM MXN and AM, whereas 50 microM DOX produced a 2-fold stimulation in lipid peroxidation. The anthracenediones also effectively inhibited DOX-stimulated lipid peroxidation with 50% inhibition occurring at 4 microM (MXN) and 6 microM (AM). Moreover, both MXN and AM potently inhibited iron (100 microM)-stimulated lipid peroxidation in rabbit hepatic microsomes with 80% inhibition produced by 15 microM anthracenedione.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2991163     DOI: 10.1007/bf00174155

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  22 in total

1.  Anthracycline antibiotic augmentation of microsomal electron transport and free radical formation.

Authors:  N R Bachur; S L Gordon; M V Gee
Journal:  Mol Pharmacol       Date:  1977-09       Impact factor: 4.436

2.  Stimulation of microsomal NADPH oxidation by quinone group-containing anticancer chemicals.

Authors:  K Handa; S Sato
Journal:  Gan       Date:  1976-08

3.  Adriamycin stimulated superoxide formation in submitochondrial particles.

Authors:  W S Thayer
Journal:  Chem Biol Interact       Date:  1977-12       Impact factor: 5.192

4.  Generation of free radicals and lipid peroxidation by redox cycling of adriamycin and daunomycin.

Authors:  J Goodman; P Hochstein
Journal:  Biochem Biophys Res Commun       Date:  1977-07-25       Impact factor: 3.575

5.  Inhibition of adriamycin-stimulated microsomal lipid peroxidation by mitoxantrone and ametantrone, two new anthracenedione antineoplastic agents.

Authors:  E D Kharasch; R F Novak
Journal:  Biochem Biophys Res Commun       Date:  1982-10-15       Impact factor: 3.575

Review 6.  The anthracycline antineoplastic drugs.

Authors:  R C Young; R F Ozols; C E Myers
Journal:  N Engl J Med       Date:  1981-07-16       Impact factor: 91.245

7.  The clinical evaluation of analogs--III. Anthracyclines.

Authors:  S K Carter
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

8.  Inhibitory effects of anthracenedione antineoplastic agents on hepatic and cardiac lipid peroxidation.

Authors:  E D Kharasch; R F Novak
Journal:  J Pharmacol Exp Ther       Date:  1983-08       Impact factor: 4.030

9.  Ametantrone inhibits prostaglandin--mediated resorption in bone organ culture.

Authors:  M R Warner; M S Rappaport; N S Krieger; R F Novak; P H Stern
Journal:  Prostaglandins       Date:  1984-10

10.  1,4-Bis(2-[(2-hydroxyethyl)amino]ethylamino)-9,10-anthracenedione, an anthraquinone antitumour agent that does not cause lipid peroxidation in vivo; comparison with daunorubicin.

Authors:  L H Patterson; B M Gandecha; J R Brown
Journal:  Biochem Biophys Res Commun       Date:  1983-01-27       Impact factor: 3.575

View more
  10 in total

Review 1.  Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.

Authors:  V B Pai; M C Nahata
Journal:  Drug Saf       Date:  2000-04       Impact factor: 5.606

Review 2.  Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.

Authors:  D Faulds; J A Balfour; P Chrisp; H D Langtry
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

3.  Downregulation of cystine transporter xc by irinotecan in human head and neck cancer FaDu xenografts.

Authors:  Sreenivasulu Chintala; Károly Tóth; Ming-Biao Yin; Arup Bhattacharya; Sylvia B Smith; M Shamsul Ola; Shousong Cao; Farukh A Durrani; Tanjima R Zinia; Rebecca Dean; Harry K Slocum; Youcef M Rustum
Journal:  Chemotherapy       Date:  2010-06-11       Impact factor: 2.544

Review 4.  Pharmacokinetics and metabolism of mitoxantrone. A review.

Authors:  G Ehninger; U Schuler; B Proksch; K P Zeller; J Blanz
Journal:  Clin Pharmacokinet       Date:  1990-05       Impact factor: 6.447

5.  Microsomal lipid peroxidation induced by adriamycin, epirubicin, daunorubicin and mitoxantrone: a comparative study.

Authors:  G F Vile; C C Winterbourn
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

6.  Lack of involvement of reactive oxygen in the cytotoxicity of mitoxantrone, CI941 and ametantrone in MCF-7 cells: comparison with doxorubicin.

Authors:  G R Fisher; L H Patterson
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

7.  Relationship between the pharmacological activity of antitumor drugs Ametantrone and mitoxantrone (Novatrone) and their ability to condense nucleic acids.

Authors:  J Kapuscinski; Z Darzynkiewicz
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

8.  Anacardic acid enhances the anticancer activity of liposomal mitoxantrone towards melanoma cell lines - in vitro studies.

Authors:  Mateusz Legut; Dominik Lipka; Nina Filipczak; Adriana Piwoni; Arkadiusz Kozubek; Jerzy Gubernator
Journal:  Int J Nanomedicine       Date:  2014-01-23

Review 9.  DNA damage and repair in human cancer: molecular mechanisms and contribution to therapy-related leukemias.

Authors:  Ida Casorelli; Cecilia Bossa; Margherita Bignami
Journal:  Int J Environ Res Public Health       Date:  2012-07-27       Impact factor: 3.390

10.  Risk and Temporal Changes of Heart Failure Among 5-Year Childhood Cancer Survivors: a DCOG-LATER Study.

Authors:  E A M Lieke Feijen; Anna Font-Gonzalez; Helena J H Van der Pal; Wouter E M Kok; Ronald B Geskus; Cécile M Ronckers; Dorine Bresters; Elvira C van Dalen; Eline van Dulmen-den Broeder; Marleen H van den Berg; Margriet van der Heiden-van der Loo; Marry M van den Heuvel-Eibrink; Flora E van Leeuwen; Jacqueline J Loonen; Sebastian J C M M Neggers; A B Birgitta Versluys; Wim J E Tissing; Leontien C M Kremer
Journal:  J Am Heart Assoc       Date:  2019-01-08       Impact factor: 5.501

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.